A real-world clinical outcomes study of alpelisib in patients with PIK3CA-mutated breast cancer
Latest Information Update: 27 May 2021
At a glance
- Drugs Alpelisib (Primary) ; Fulvestrant
- Indications Breast cancer
- Focus Therapeutic Use
- 27 May 2021 New trial record
- 20 May 2021 according to a Foundation Medicine media release, this study was conducted in partnership with UCSF Helen Diller Family Comprehensive Cancer Center.
- 20 May 2021 Results presented in a Foundation Medicine media release.